Cencora Set to Report Fiscal Q4 2026 Results Nov. 4; Analysts Forecast 17.5% EPS Growth

Cencora, Inc. (COR) will report fiscal Q4 2026 results before the market opens on Wednesday, Nov. 4, with analysts forecasting adjusted EPS of $4.51, up 17.5% from $3.84 a year earlier. For the full fiscal year, consensus projects adjusted EPS of $17.87, an 11.7% increase from $16 in fiscal 2025. The pharmaceutical distributor beat bottom-line estimates in three of the past four quarters. In Q3 2026, adjusted EPS reached $4.48 and revenue rose to $84.75 billion, both topping consensus on strong specialty medicine and GLP-1 drug demand. Revenue at its largest unit, U.S. Healthcare, grew 4.9% to $74.86 billion. Shares rose 3.6% on Aug. 5 after the company raised its annual adjusted EPS forecast to $17.75–$17.95 while maintaining revenue growth guidance of 4%–6%. COR stock has risen marginally over the past 52 weeks, trailing the S&P 500 Index's ($SPX) 13.1% gain and the Health Care Select Sector SPDR ETF's (XLV) 22.8% return. The stock carries a "Strong Buy" consensus rating from 14 analysts, with an average price target of $366.85, implying 10.8% upside.